Review Article
Role of Inflammation in Classification of Diabetic Macular Edema by Optical Coherence Tomography
Table 1
Agents currently in clinical trials as treatments for inflammation in diabetic macular edema.
| Drug class | Molecule | Administration | Trial number | Trial status |
| Steroid | Betamethasone microsphere | Posterior sub-Tenon | NCT01411254 | Phase 2/3 completed | Dexamethasone-cyclodextrin | Topical | NCT01523314 | Unknown | Danazol | Oral | NCT02002403 | Phase 2 completed | NOVA63035 | Intravitreal | NCT00665106 | Phase 1 completed | TNF alpha inhibitor | Infliximab | Intravitreal | NCT00959725 | Unknown | Tie-2 activator | AKB-9778 | Subcutaneous | NCT02050828 | Phase 2 completed | IGF-1 antagonist | Teprotumumab | Intravenous | NCT02103283 | Phase 1 completed | Integrin antagonist | SF0166 | Topical | NCT02914613 | Phase 1/2 completed | mTOR inhibitor | Sirolimus | Subconjunctival | NCT00711490 | Phase 1/2 completed |
|
|
IGF = insulin-like growth factor; mTOR = mechanistic target of rapamycin; TNF = tumor necrosis factor.
|